

Viktar M Mitsura

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2609630/publications.pdf>

Version: 2024-02-01

75
papers

3,406
citations

218677

26
h-index

144013

57
g-index

75
all docs

75
docs citations

75
times ranked

4100
citing authors

#	ARTICLE	IF	CITATIONS
1	Liver-Related Deaths in Persons Infected With the Human Immunodeficiency Virus. <i>Archives of Internal Medicine</i> , 2006, 166, 1632.	3.8	1,004
2	Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. <i>Aids</i> , 2010, 24, 1667-1678.	2.2	353
3	HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. <i>Aids</i> , 2008, 22, 2143-2153.	2.2	207
4	Feasibility and Effectiveness of Indicator Condition-Guided Testing for HIV: Results from HIDES I (HIV Tj ETQq0 0 0 rgBT /Overlock 10 Tf	2.5	145
5	Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study. <i>PLoS Medicine</i> , 2015, 12, e1001809.	8.4	119
6	Variable Impact on Mortality of AIDSâ€Defining Events Diagnosed during Combination Antiretroviral Therapy: Not All AIDSâ€Defining Conditions Are Created Equal. <i>Clinical Infectious Diseases</i> , 2009, 48, 1138-1151.	5.8	108
7	Doravirine versus ritonavir-boosted darunavir in antiretroviral-naïve adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial. <i>Lancet HIV</i> , 2018, 5, e211-e220.	4.7	108
8	Loss to followâ€up in an international, multicentre observational study. <i>HIV Medicine</i> , 2008, 9, 261-269.	2.2	91
9	Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: a cohort study. <i>BMC Infectious Diseases</i> , 2013, 13, 471.	2.9	68
10	Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients. <i>Aids</i> , 2012, 26, 1917-1926.	2.2	62
11	Tuberculosis-related mortality in people living with HIV in Europe and Latin America: an international cohort study. <i>Lancet HIV</i> , 2016, 3, e120-e131.	4.7	53
12	Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 46, 607-615.	2.1	47
13	Liver-related death among HIV/hepatitis C virus-co-infected individuals. <i>Aids</i> , 2015, 29, 1205-1215.	2.2	46
14	Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA. <i>Aids</i> , 2008, 22, 367-376.	2.2	43
15	HIV-1 molecular transmission clusters in nine European countries and Canada: association with demographic and clinical factors. <i>BMC Medicine</i> , 2019, 17, 4.	5.5	43
16	Auditing HIV Testing Rates across Europe: Results from the HIDES 2 Study. <i>PLoS ONE</i> , 2015, 10, e0140845.	2.5	43
17	Dialysis and Renal Transplantation in HIV-Infected Patients: a European Survey. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 55, 582-589.	2.1	42
18	Predictors of <sc>CD</sc>4 cell recovery following initiation of antiretroviral therapy among <sc>HIV</sc>â€1 positive patients with wellâ€estimated dates of seroconversion. <i>HIV Medicine</i> , 2018, 19, 184-194.	2.2	41

#	ARTICLE	IF	CITATIONS
19	Increased non-AIDS mortality among persons with AIDS-defining events after antiretroviral therapy initiation. <i>Journal of the International AIDS Society</i> , 2018, 21, e25031.	3.0	38
20	Infection-related and -unrelated malignancies, HIV and the aging population. <i>HIV Medicine</i> , 2016, 17, 590-600.	2.2	37
21	Immuno-Virological Discordance and the Risk of Non-AIDS and AIDS Events in a Large Observational Cohort of HIV-Patients in Europe. <i>PLoS ONE</i> , 2014, 9, e87160.	2.5	35
22	Hepatitis C seroconversions in HIV infection across Europe: which regions and patient groups are affected?. <i>Liver International</i> , 2015, 35, 2384-2391.	3.9	33
23	Regional Differences in AIDS and Non-AIDS Related Mortality in HIV-Positive Individuals across Europe and Argentina: The EuroSIDA Study. <i>PLoS ONE</i> , 2012, 7, e41673.	2.5	32
24	Multicenter European Prevalence Study of Neurocognitive Impairment and Associated Factors in HIV Positive Patients. <i>AIDS and Behavior</i> , 2018, 22, 1573-1583.	2.7	32
25	Improving the evidence for indicator condition guided HIV testing in Europe: Results from the HIDES II Study 2012-2015. <i>PLoS ONE</i> , 2019, 14, e0220108.	2.5	31
26	Short- and long-term mortality and causes of death in HIV/tuberculosis patients in Europe. <i>European Respiratory Journal</i> , 2014, 43, 166-177.	6.7	30
27	Hyaluronic Acid Levels Predict Risk of Hepatic Encephalopathy and Liver-Related Death in HIV/Viral Hepatitis Coinfected Patients. <i>PLoS ONE</i> , 2013, 8, e64283.	2.5	25
28	Deteriorating renal function and clinical outcomes in HIV-positive persons. <i>Aids</i> , 2014, 28, 727-737.	2.2	25
29	Uptake of hepatitis C virus treatment in HIV/hepatitis C virus-coinfected patients across Europe in the era of direct-acting antivirals. <i>Aids</i> , 2018, 32, 1995-2004.	2.2	24
30	Self-Reported Decline in Everyday Function, Cognitive Symptoms, and Cognitive Function in People With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, e74-e83.	2.1	23
31	Evaluating the Impact of Functional Genetic Variation on HIV-1 Control. <i>Journal of Infectious Diseases</i> , 2017, 216, 1063-1069.	4.0	20
32	People who inject drugs remain hard-to-reach population across all HIV continuum stages in Central, Eastern and South Eastern Europe - data from Euro-guidelines in Central and Eastern Europe Network. <i>Infectious Diseases</i> , 2019, 51, 277-286.	2.8	20
33	A376S in the Connection Subdomain of HIV-1 Reverse Transcriptase Confers Increased Risk of Virological Failure to Nevirapine Therapy. <i>Journal of Infectious Diseases</i> , 2011, 204, 741-752.	4.0	19
34	Major differences in organization and availability of health care and medicines for HIV/TB coinfecting patients across Europe. <i>HIV Medicine</i> , 2015, 16, 544-552.	2.2	19
35	Euroguidelines in Central and Eastern Europe (ECEE) conference and the Warsaw Declaration - a comprehensive meeting report. <i>HIV Medicine</i> , 2017, 18, 370-375.	2.2	19
36	Temporal trends of transmitted HIV drug resistance in a multinational seroconversion cohort. <i>Aids</i> , 2018, 32, 161-169.	2.2	19

#	ARTICLE	IF	CITATIONS
37	Reference curves for <sc>CD</sc>4 Tâ€cell count response to combination antiretroviral therapy in <sc>HIV</sc>â€1â€infected treatmentâ€naÃve patients. HIV Medicine, 2017, 18, 33-44.	2.2	16
38	Management of MDR-TB in HIV co-infected patients in Eastern Europe: Results from the TB:HIV study. Journal of Infection, 2018, 76, 44-54.	3.3	16
39	<sc>HIV</sc> incidence in the Estonian population in 2013 determined using the <sc>HIV</sc>â€1 limiting antigen avidity assay. HIV Medicine, 2018, 19, 33-41.	2.2	15
40	Low compliance with hepatocellular carcinoma screening guidelines in hepatitis B/C virus coâ€infected HIV patients with cirrhosis. Journal of Viral Hepatitis, 2019, 26, 1224-1228.	2.0	15
41	The extent of Bâ€cell activation and dysfunction preceding lymphoma development in <sc>HIV</sc>â€positive people. HIV Medicine, 2018, 19, 90-101.	2.2	14
42	Risk for Nonâ€AIDS-Defining and AIDS-Defining Cancer of Early Versus Delayed Initiation of Antiretroviral Therapy. Annals of Internal Medicine, 2021, 174, 768-776.	3.9	14
43	Uptake and effectiveness of two-drug compared with three-drug antiretroviral regimens among HIV-positive individuals in Europe. Aids, 2019, 33, 2013-2024.	2.2	13
44	Reduction in undiagnosed HIV infection in the European Union/European Economic Area, 2012 to 2016. Eurosurveillance, 2017, 22, .	7.0	12
45	Persistent disparities in antiretroviral treatment (ART) coverage and virological suppression across Europe, 2004 to 2015. Eurosurveillance, 2018, 23, .	7.0	12
46	Increased incidence of antiretroviral drug discontinuation among patients with viremic hepatitis C virus coinfection and high hyaluronic acid, a marker of liver fibrosis. Aids, 2014, 28, 577-587.	2.2	11
47	Changing utilization of Stavudine (d4T) in HIVâ€positive people in 2006â€2013 in the EuroSIDA study. HIV Medicine, 2015, 16, 533-543.	2.2	11
48	TB Meningitis in HIV-Positive Patients in Europe and Argentina: Clinical Outcome and Factors Associated with Mortality. BioMed Research International, 2013, 2013, 1-9.	1.9	10
49	DECOLONIZATION OF INTESTINAL CARRIAGE OF MDR/XDR GRAM-NEGATIVE BACTERIA WITH ORAL COLISTIN IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES: RESULTS OF A RANDOMIZED CONTROLLED TRIAL. Mediterranean Journal of Hematology and Infectious Diseases, 2017, 10, 2018030.	1.3	10
50	Thrombocytopenia is associated with an increased risk of cancer during treated HIV disease. Aids, 2014, 28, 2565-2571.	2.2	9
51	Establishing a hepatitis C continuum of care among <sc>HIV</sc>/hepatitis C virusâ€coinfected individuals in Euro<sc>SIDA</sc>. HIV Medicine, 2019, 20, 264-273.	2.2	9
52	Antiretroviral pill count and clinical outcomes in treatmentâ€naÃve patients with <sc>HIV</sc> infection. HIV Medicine, 2018, 19, 132-142.	2.2	8
53	<sc>HIV</sc> health care providers are ready to introduce preâ€exposure prophylaxis in Central and Eastern Europe and neighbouring countries: data from the Euroguidelines in Central and Eastern Europe (<sc>ECEE</sc>) Network Group. HIV Medicine, 2018, 19, 629-633.	2.2	8
54	Immunological and virological response to antiretroviral treatment in migrant and native men and women in Western Europe; is benefit equal for all?. HIV Medicine, 2018, 19, 42-48.	2.2	8

#	ARTICLE	IF	CITATIONS
55	Health care index score and risk of death following tuberculosis diagnosis in HIV-positive patients. <i>International Journal of Tuberculosis and Lung Disease</i> , 2013, 17, 198-206.	1.2	7
56	Predictors of CD4+ T-Cell Counts of HIV Type 1 "Infected Persons After Virologic Failure of All 3 Original Antiretroviral Drug Classes. <i>Journal of Infectious Diseases</i> , 2013, 207, 759-767.	4.0	7
57	Long term effectiveness of once-daily unboosted atazanavir plus abacavir/lamivudine as a switch strategy in subjects with virological suppression. <i>Journal of the International AIDS Society</i> , 2014, 17, 19810.	3.0	7
58	Scale "up of <sc>HIV</sc> self "testing. <i>HIV Medicine</i> , 2018, 19, e72.	2.2	7
59	Comparison of Single and Boosted Protease Inhibitor Versus Nonnucleoside Reverse Transcriptase Inhibitor "Containing cART Regimens in Antiretroviral-Na "ve Patients Starting cART After January 1, 2000. <i>HIV Clinical Trials</i> , 2006, 7, 271-284.	2.0	6
60	Incidence of cancer and overall risk of mortality in individuals treated with raltegravir "based and non "raltegravir "based combination antiretroviral therapy regimens. <i>HIV Medicine</i> , 2018, 19, 102-117.	2.2	6
61	Healthcare delivery for HIV "positive people with tuberculosis in Europe. <i>HIV Medicine</i> , 2021, 22, 283-293.	2.2	6
62	State of viral hepatitis care in 16 countries of Central and Eastern European Region. <i>Central European Journal of Public Health</i> , 2019, 27, 212-216.	1.1	6
63	One-year mortality of HIV-positive patients treated for rifampicin- and isoniazid-susceptible tuberculosis in Eastern Europe, Western Europe, and Latin America. <i>Aids</i> , 2017, 31, 375-384.	2.2	5
64	Uptake of Tenofovir-Based Antiretroviral Therapy among HIV "HBV-Coinfected Patients in the EuroSIDA Study. <i>Antiviral Therapy</i> , 2018, 23, 405-413.	1.0	5
65	Where is the greatest impact of uncontrolled HIV infection on AIDS and non-AIDS events in HIV?. <i>Aids</i> , 2018, 32, 205-215.	2.2	5
66	Effect of incident hepatitis C infection on CD4+ cell count and HIV RNA trajectories based on a multinational HIV seroconversion cohort. <i>Aids</i> , 2019, 33, 327-337.	2.2	5
67	A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe. <i>Infection</i> , 2014, 42, 757-762.	4.7	4
68	Long "term effectiveness of recommended boosted protease inhibitor "based antiretroviral therapy in Europe. <i>HIV Medicine</i> , 2018, 19, 324-338.	2.2	4
69	Prevalence and outcomes of pregnancies in women with HIV over a 20-year period. <i>Aids</i> , 2021, 35, 2025-2033.	2.2	4
70	Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression. <i>Medicine (United States)</i> , 2016, 95, e5020.	1.0	2
71	Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort. <i>HIV Medicine</i> , 2018, 19, 252-260.	2.2	2
72	Reversible Spatial Filter Of The Type "Photosensitive Organic Polymer - Liquid Crystal" For Holographic Application. , 1990, 1183, 28.		1

#	ARTICLE	IF	CITATIONS
73	Molecular and genetic properties of hepatitis b virus and their clinical role in chronic hepatitis B. HIV Infection and Immunosuppressive Disorders, 2021, 12, 43-50.	0.3	1
74	RESULTS OF THE USE OF SOFOSBUVIR IN COMBINATION WITH LEDIPASVIR OR DACLATASVIR FOR CHRONIC HEPATITIS C TREATMENT IN THE REPUBLIC OF BELARUS. Jurnal Infektologii, 2018, 10, 77-83.	0.3	1
75	The diagnostic value of indirect markers of liver fibrosis in patients with chronic hepatitis B. Jurnal Infektologii, 2020, 12, 73-79.	0.3	0